spacer
home > ebr > autumn 2018 > protein progression
PUBLICATIONS
European Biopharmaceutical Review

Protein Progression

Microarrays offer a well-established bioanalytical format for high-throughput studies of many different biomolecules. In the field of peptide and protein microarrays, great progress has been achieved in immobilising large numbers of native target molecules, such as recombinant human proteins or peptide libraries to microarray surfaces. With an increased content at high quality, protein and peptide microarrays offer new possibilities in proteomics and pharmaceutical R&D. Simultaneously, label-free sensing has evolved from highly sophisticated, but low-throughput, to powerful multiplexed screening tools. The combination of these advancements opens a new field of bioanalytics.

Analysis at a Glance

Proteins are involved in almost any process of a living cell. Therefore, proteomics is a key discipline of modern life sciences today. Furthermore, protein-protein interactions of human cells (the so-called human interactome, see Figure 1) and the interactions of proteins with other biomolecules are key for understanding any physiological process and manipulating it (eg, by a pharmaceutical or biopharmaceutical drug).

Protein scientists have developed different bioanalytical approaches based on proteins immobilised in a microarray format. Here, the focus lies on protein microarrays representing a set of species-specific (in most cases, human) proteins to study the binding of a specific molecule or sample to these target proteins in a single assay. The trend is towards a fraction up to the complete genetically encoded proteome.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Güenther Proll is Co-Founder and Managing Director at Biametrics and has more than 18 years’ experience in optical biosensing. Güenther’s work is focussed on the characterisation and development of optical transduction technologies, spatially resolved surface chemistry on diverse substrates, and multianalyte/multiplex assay developments. He holds a diploma in technical biology from the University of Stuttgart, Germany, and a PhD in physical chemistry from the University of Tuebingen, Germany.
spacer
Dr Güenther Proll
spacer
spacer
Print this page
Send to a friend
Privacy statement

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement